We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Bronchoalveolar Lavage Cell Pattern Determined for Diffuse Alveolar Hemorrhage

By LabMedica International staff writers
Posted on 11 Oct 2021
Print article
Image: Characteristic bronchoalveolar lavage findings of diffuse alveolar hemorrhage (Photo courtesy of Peter C. Bauer, MD)
Image: Characteristic bronchoalveolar lavage findings of diffuse alveolar hemorrhage (Photo courtesy of Peter C. Bauer, MD)
Diffuse alveolar hemorrhage (DAH) is a clinicopathological syndrome that describes the accumulation of intra-alveolar red blood cells originating from the alveolar capillaries. DAH can induce severe respiratory failure.

Bronchoalveolar lavage (BAL) is an essential DAH diagnostic method. The BAL fluid (BALF) of DAH presents visually hemorrhagic and cytologically hemosiderin-laden macrophages. Antithrombotic therapy (AT) is known to be one of the causes of DAH, and other etiologies can induce DAH during AT.

Respiratory Specialists at the Osaka Police Hospital (Osaka-City, Japan) conducted a retrospective cohort study of patients admitted between October 2008 and July 2020. The study aim was to identify prognostic factors of DAH, especially bronchoalveolar lavage fluids (BALF) cell pattern. In the study, DAH was defined by the following criteria: Clinical and radiological presentation that was compatible with a diagnosis of DAH, and Bronchoalveolar lavage fluids (BALF) that was macroscopically bloody or cytologically contained hemosiderin-burden macrophages. Infection was confirmed when the specific microorganism was identified by culture or serological test. The team included 68 patients in their analysis with a median age was 75 (72–80) years, and 49 (72%) patients were male.

The investigators reported that in-hospital mortality was 26.5%. Variables associated with in-hospital death were neutrophils percentage in BALF ≥ 44.5% [Odds Ratio (OR) 16.0, 95% confidence interval (CI) 4.33–58.9)], lymphocytes percentage in BALF < 14% (OR 7.44, 95% CI 2.11–26.2), idiopathic DAH (OR 0.31, 95% CI 0.10–0.95), oxygen flow ≥ 4L/min (OR 3.90, 95% CI 1.20–12.6), and estimated glomerular filtration rate < 60 mL/min (OR 5.00, 95%CI 1.29–19.4). In-hospital mortality was significantly higher in patients with neutrophils percentage ≥ 44.5% and lymphocytes percentage < 14% compared with patients with neutrophils percentage < 44.5% and lymphocytes percentage ≥ 14%.

The authors concluded that a higher neutrophils percentage in BALF was found to be significantly associated with in-hospital mortality. On the other hand, a higher lymphocytes percentage in BALF was correlated with lower mortality. The study was published on September 9, 2021 in the journal BMC Pulmonary Medicine.

Related Links:
Osaka Police Hospital

Gold Supplier
Hemostasis Analyzer
STA R Max 3
Bulk Sorter
Assayed Hemoglobin Control
Cytology Sample Processor
SDSCP9000 CytoPath Processor

Print article


Molecular Diagnostics

view channel
Image: Absence of nuclear immunohistochemical staining of MSH2 protein (A) and presence of MLH1 protein (B) in urothelial cell carcinoma of the urinary bladder of a patient carrying a germline MSH2 mutation. Observe the nuclear staining in stromal cells as an internal control (Photo courtesy of Radboud University Nijmegen Medical Centre)

Simple Urine Test Detects Urothelial Cancers in Lynch Syndrome Patients

Lynch Syndrome (LS) is an inherited genetic disorder that carries a high risk of cancer. LS is caused by mutations affecting MLH1, MSH2, MSH6 or PMS2 genes. More than one in 300 people have LS but most... Read more


view channel
Image: The Gazelle Hb Variant Test for screening, diagnosis and management of sickle cell disease and related hemoglobinopathies at the point of care (Photo courtesy of Hemex Health)

Point-of-Care Device Accurately Rapidly Diagnoses Sickle Cell Disease

Hemoglobinopathies are the most common autosomal hereditary disorders. Approximately 7% of the global population carries hemoglobin gene mutation including structural hemoglobin variants like sickle hemoglobin... Read more


view channel
Image: The IMMULITE 2000 XPi Immunoassay System provides multiple tests on a single, easy-to-use analyzer, including the thyroid-stimulating immunoglobulin assay (Photo courtesy of Siemens Healthcare)

Immunoassays Evaluated for Thyroid-Stimulating Receptor Antibody in Graves’ Disease

Graves' disease (GD), also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid. It frequently results in and is the most common cause of hyperthyroidism and it also often results... Read more


view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more


view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more


view channel

Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases

The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.